medigraphic.com
Colegio de Medicina Interna de México.

2007, Number 5

<< Back Next >>

Med Int Mex 2007; 23 (5)

Commentaries on the treatment of hypertension

Fonseca RS

Language: Spanish
References: 24
Page: 415-423
PDF size: 191.92 Kb.


ABSTRACT

Hypertension is one of the most prevalent cardiovascular risk factors in the world. Its treatment and control have been proved to markedly reduce cardiovascular morbid-mortality. During the last few years the patient percentage management of well controlled individuals (BP ‹ 140/90 mmHg), but is still too low. There are a myriad of reasons that explain this phenomenon. One very important reason is that the general and specialist physician are not making optimal use of the available pharmacological therapeutics in order to obtain greater arterial hypertension control. The purpose of this paper is to comment on some of the most important situations related to the treatment of hypertension and to make a few recommendations that are put into practice in a hypertension clinic, but can be used in daily practice with patients at any attention level for this illness.


REFERENCES

  1. Kearney PM, Whelton M, Reynolds K, Muntner P, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23.

  2. Kottke TE, Stroebel RJ, Hoffman RS. JNC 7-It’s more than high blood pressure. JAMA 2003;289:2573-4.

  3. Velázquez-Monroy O, Rosas-Peralta M, Lara-Esqueda A, Pastelín- Hernández G. Hipertensión arterial en México: resultados de la Encuesta Nacional de Salud (ENSA) 2000. Arch Cardiol Mex 2002;72:71-84.

  4. Rosas-Peralta M, Lara-Esqueda A, Pastelín-Hernández G, Velásquez-Monroy O, et al. Re-encuesta Nacional de Hipertensión Arterial (RENAHTA): Consolidación Mexicana de los Factores de Riesgo Cardiovascular. Cohorte Nacional de Seguimiento. Arch Cardiol Mex 2005;75:96-111.

  5. Hayman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United Status. N Engl J Med 2001;345:479-86.

  6. Chobanian AV, Bakris GL, Black HR, Cushman WC, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.

  7. European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.

  8. Whitworth JA, World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-92.

  9. NHS. NICE clinical guideline 34. Hypertension: management of hypertension in adults in primary care. Issue date. British Hypertension Society. Dirección URL: [consulta: junio 2006].

  10. Fonseca-Reyes S, de Alba-García J, Parra-Carrillo JZ, Paczka- Zapata JA. Effect of standard cuff on blood pressure readings in patients with obese arms. How frequent are arms of a “large circumference”? Blood Press Monit 2003;8:101-10.

  11. Pickering TG, Hall JE, Appel LJ, Falkner BE, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans. Hypertension 2005;45:142-61.

  12. Fonseca-Reyes S, Parra-Carrillo JZ. Diagnóstico de hipertensión arterial. Más allá de la medición convencional. Nefrol Mex 2001;21(4):199-206.

  13. Fonseca-Reyes S, Parra-Carrillo JZ, Chávez-Michel J. Hipertensión de la Bata Blanca. Implicaciones en la clínica. Med Intern Mex 1999;15(6):264-68.

  14. PROGRESS Collaborative Study Group. Randomized trial of perindopril based blood pressure lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.

  15. Yusuf S, Sleigth P, Pogue J, Bosch J, et al. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Herat Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.

  16. Khan NA, Hemmelgarn B, Padwal R, Larochelle P, et al. The 2006 Canadian Hypertension Education Program Recommendations for the Management of Hypertension. Part 2: therapy. Can J Cardiol 2007;23:539-50.

  17. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344:3-10.

  18. Fonseca-Reyes S, Montes-Casillas M, López-Maldonado FJ, Bravo-Barba N, Parra-Carrillo JZ. Prescripción de antihipertensivos y efectos adversos en una clínica de hipertensión. Presentado en el IV Congreso Latinoamericano de Hipertensión. Arch Ven Farmacol Ter 2004;23(1):S32.

  19. Carter BL, Ernst ME, Cohen JD. Hydrochlorotiazide versus chlortalidone. Hypertension 2004;43:4-9.

  20. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.

  21. Moser M, Cushman W, Handler J. Resistant or difficult-to-treat hypertension. J Clin Hypertens 2006;8:434-40.

  22. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and development of diabetes. A quantitative review. Hypertension 2006;48:219-24

  23. Cutler J. Thiazide-associated glucose abnormalities: prognosis, etiology, and prevention. Is potassium balance the key? Hypertension 2006;48:198-200.

  24. Fonseca-Reyes S, Parra-Carrillo JZ. Recomendaciones para el tratamiento de la hipertensión en adultos. Med Int Mex 2004;20:296-305.




2020     |     www.medigraphic.com